A Compelling Opportunity

Clarus’ proprietary adjuvant is fully developed and successfully tested in multiple pre-clinical studies. Based on these results, and its applicability across multiple segments of the life sciences industry, we believe CBI-3A provides a unique solution to existing vaccine market challenges. In addition, our business development strategy is designed to exploit key differences in entry to applicable market segments, reducing risk and accelerating to positive cash flow.

Please contact us if you would like to know more about this unique and compelling investment opportunity.

View and Download Key Investment Information Below:

Investor Presentation

Investor Questionnaire

At Clarus Biologics our mission is to increase the availability of safe and effective prophylactic and therapeutic technologies.

Contact Now

(919)946-1222

DDasburg@clarusbiologics.com

408 Dragonfly Trail

Chapel Hill, NC, USA

Copyright © 2024 - Clarus Biologics Inc.